|
86 Companies |
|
137 Products |
|
137 Products |
|
85 Mechanisms of Action |
|
4 Trials |
|
2019 News |
|
| «12...2728293031323334353637...3940» |
- Enrollment change: Effect of Single Dose Intranasal Insulin On Cognitive Function (clinicaltrials.gov) - Dec 16, 2012
P4, N=30, Completed, Sponsor: University of Massachusetts, Worcester
N=39 --> 30
- modafinil / Generic mfg.
Enrollment change: Modafinil for Treatment of Cognitive Dysfunction in Schizophrenia (clinicaltrials.gov) - Dec 12, 2012
P4, N=38, Completed, Sponsor: University of California, Davis
N=39 --> 30 N=80 --> 38
- ||||||| Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J
Trial completion: A Study of Paliperidone Palmitate in Japanese Patients With Schizophrenia (clinicaltrials.gov) - Dec 12, 2012
P3, N=201, Completed, Sponsor: Janssen Pharmaceutical K.K.
N=80 --> 38 Active, not recruiting --> Completed
- modafinil / Generic mfg.
Trial completion: Modafinil for Treatment of Cognitive Dysfunction in Schizophrenia (clinicaltrials.gov) - Dec 12, 2012
P4, N=38, Completed, Sponsor: University of California, Davis
Active, not recruiting --> Completed Recruiting --> Completed
- Trial termination: Contingency Management for Smoking Cessation Among Veterans With Psychotic Disorders (clinicaltrials.gov) - Dec 11, 2012
P=N/A, N=23, Terminated, Sponsor: Department of Veterans Affairs
Recruiting --> Completed Recruiting --> Terminated; Stopped due to low recruitment.
- Enrollment change: Recovery From Psychosis in Schizophrenia - The Impact of Cognitive-Behavioral Therapy (clinicaltrials.gov) - Dec 11, 2012
P=N/A, N=34, Completed, Sponsor: New York State Psychiatric Institute
Recruiting --> Terminated; Stopped due to low recruitment. N=72 --> 34
- Enrollment change: Contingency Management for Smoking Cessation Among Veterans With Psychotic Disorders (clinicaltrials.gov) - Dec 11, 2012
P=N/A, N=23, Terminated, Sponsor: Department of Veterans Affairs
N=72 --> 34 N=100 --> 23
- Trial completion: Recovery From Psychosis in Schizophrenia - The Impact of Cognitive-Behavioral Therapy (clinicaltrials.gov) - Dec 11, 2012
P=N/A, N=34, Completed, Sponsor: New York State Psychiatric Institute
N=100 --> 23 Recruiting --> Completed
- ||| Clinical: The Management of Schizophrenia in Clinical Practice (MOSAIC) (clinicaltrials.gov) - Dec 6, 2012
P=N/A, N=2500, Recruiting, Sponsor: Genentech
- | risperidone / Generic mfg., paliperidone extended release / Generic mfg.
Enrollment open: A Study to Evaluate the Effect of Oral Paliperidone Extended-Release and Oral Risperidone Immediate-Release on Cognitive Function in Clinically Stable Patients With Schizophrenia (clinicaltrials.gov) - Dec 6, 2012
P4, N=50, Recruiting, Sponsor: Johnson & Johnson Taiwan Ltd
Recruiting --> Completed Not yet recruiting --> Recruiting
- Abilify Maintena (aripiprazole extended release) / Otsuka, Lundbeck
Trial termination: ARRIVE- EU: Open-label Study to Compare Hospitalization Rates of Schizophrenic Patients Treated With Oral Antipsychotics Versus IM Depot Aripiprazole (clinicaltrials.gov) - Dec 4, 2012
P3, N=30, Terminated, Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
Not yet recruiting --> Recruiting Recruiting --> Terminated
- Abilify Maintena (aripiprazole extended release) / Otsuka, Lundbeck
Enrollment change: ARRIVE- EU: Open-label Study to Compare Hospitalization Rates of Schizophrenic Patients Treated With Oral Antipsychotics Versus IM Depot Aripiprazole (clinicaltrials.gov) - Dec 4, 2012
P3, N=30, Terminated, Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
Recruiting --> Terminated N=500 --> 30
- amisulpride / Generic mfg., clozapine / Generic mfg.
Enrollment open: Clozapine Versus Amisulpride in Treatment-resistant Schizophrenia Patients (clinicaltrials.gov) - Dec 3, 2012
P=N/A, N=140, Recruiting, Sponsor: Geha Mental Health Center
N=500 --> 30 Not yet recruiting --> Recruiting
- Trial completion: Prevention of Weight Gain in Early Psychoses (clinicaltrials.gov) - Dec 3, 2012
P=N/A, N=70, Completed, Sponsor: Centre for Addiction and Mental Health
Not yet recruiting --> Recruiting Recruiting --> Completed
- ||||||| Nuplazid (pimavanserin) / Acadia Pharma
Trial completion: A Study of the Safety and Efficacy of Pimavanserin in Patients With Parkinson's Disease Psychosis (clinicaltrials.gov) - Dec 2, 2012
P3, N=199, Completed, Sponsor: ACADIA Pharmaceuticals Inc.
Recruiting --> Completed Recruiting --> Completed
- Enrollment open: Insight in Persons Presenting Schizophrenia or Related Troubles During Hospitalization in Psychiatry (clinicaltrials.gov) - Nov 29, 2012
P=N/A, N=250, Recruiting, Sponsor: Centre Hospitalier Esquirol
Recruiting --> Completed Not yet recruiting --> Recruiting
- |||| Biomarker, Trial completion: Metabolic Signatures and Biomarkers in Schizophrenia (clinicaltrials.gov) - Nov 28, 2012
P4, N=71, Completed, Sponsor: Duke University
Not yet recruiting --> Recruiting Recruiting --> Completed
- | Trial initiation date: CHANGE -it is About Life (clinicaltrials.gov) - Nov 26, 2012
P3, N=450, Not yet recruiting, Sponsor: Mental Health Services in the Capital Region, Denmark
Recruiting --> Completed Initiation date: Aug 2012 --> Dec 2012
- Trial completion: Assessment of Cannabis Craving in Schizophrenia Using Virtual Reality (clinicaltrials.gov) - Nov 26, 2012
P=N/A, N=25, Completed, Sponsor: National Institute on Drug Abuse (NIDA)
Initiation date: Aug 2012 --> Dec 2012 Recruiting --> Completed
- | New P1/2 trial: tDCS to Enhance Cognitive Training in Schizophrenia (clinicaltrials.gov) - Nov 25, 2012
P1/2, N=52, Recruiting, Sponsor: The University of New South Wales
- Enrollment open: Understanding How Cognitive Remediation Works (clinicaltrials.gov) - Nov 25, 2012
P=N/A, N=244, Recruiting, Sponsor: Boston University
Recruiting --> Completed Not yet recruiting --> Recruiting
- lurasidone / Generic mfg.
New P2 trial: Study of Lurasidone in Treating Antipsychotic Naive or Quasi-Naive Children and Adolescents (clinicaltrials.gov) - Nov 19, 2012
P2, N=30, Active, not recruiting, Sponsor: University of North Carolina, Chapel Hill
- Enrollment change: Intranasal Insulin Treatment in Patients With Schizophrenia (clinicaltrials.gov) - Nov 14, 2012
P4, N=45, Completed, Sponsor: University of Massachusetts, Worcester
Not yet recruiting --> Recruiting N=60 --> 45
- |||||||||| Rexulti (brexpiprazole) / Lundbeck, Otsuka
New P3 trial: A Study of Flexible-dose Brexpiprazole as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder, the Delphinus Trial (clinicaltrials.gov) - Nov 14, 2012
P3, N=1785, Recruiting, Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
- Trial completion: Intranasal Insulin Treatment in Patients With Schizophrenia (clinicaltrials.gov) - Nov 14, 2012
P4, N=45, Completed, Sponsor: University of Massachusetts, Worcester
N=60 --> 45 Recruiting --> Completed
- || Trial initiation date: RECONNECT-S: Observe Real-life Allocation of Atypical Antipsychotics in the Acute Inpatient Management of Schizophrenia (clinicaltrials.gov) - Nov 13, 2012
P=N/A, N=1076, Completed, Sponsor: AstraZeneca
Recruiting --> Completed Initiation date: Apr 2012 --> Jul 2012
- ||||| Risperdal Consta (risperidone depot formulation) / J&J
New P4 trial: Switching From Oral Antipsychotics to Long-Acting Risperidone in Participants With Schizophrenia (clinicaltrials.gov) - Nov 12, 2012
P4, N=53, Completed, Sponsor: Janssen-Cilag Ltd.
- | encenicline (EVP-6124) / Forum Pharmaceuticals, Mitsubishi Tanabe
Enrollment open: Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy (clinicaltrials.gov) - Nov 12, 2012
P3, N=700, Recruiting, Sponsor: FORUM Pharmaceuticals Inc
Initiation date: Apr 2012 --> Jul 2012 Not yet recruiting --> Recruiting
- |||||| encenicline (EVP-6124) / Forum Pharmaceuticals, Mitsubishi Tanabe
Enrollment open: Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy (clinicaltrials.gov) - Nov 12, 2012
P3, N=700, Recruiting, Sponsor: EnVivo Pharmaceuticals, Inc.
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- New P1 trial: Deep Brain Stimulation (DBS) for the Management of Treatment Refractory Negative Symptoms in Schizophrenia (clinicaltrials.gov) - Nov 8, 2012
P1, N=6, Recruiting, Sponsor: Centre for Addiction and Mental Health
- | New P4 trial: A Trial of Folate With B12 in Patients With Schizophrenia With Residual Symptoms in Ethiopia (clinicaltrials.gov) - Nov 7, 2012
P4, N=240, Not yet recruiting, Sponsor: Massachusetts General Hospital
- ||||| paliperidone extended release / Generic mfg.
New P4 trial: PERFLEX: Tolerability, Safety and Efficacy of Flexibly Dosed Paliperidone ER in Patients With Schizophrenia (clinicaltrials.gov) - Nov 7, 2012
P4, N=95, Completed, Sponsor: Janssen-Cilag, S.A.
- Serlect (sertindole) / Lundbeck, Abbott
Trial termination, Head-to-Head: Comparing the Effects of Sertindole and Olanzapine on Cognition (SEROLA) (clinicaltrials.gov) - Nov 5, 2012
P=N/A, N=11, Terminated, Sponsor: University of Aarhus
Not yet recruiting --> Recruiting Recruiting --> Terminated; Due to recruitment problems
- Serlect (sertindole) / Lundbeck, Abbott
Enrollment change, Head-to-Head: Comparing the Effects of Sertindole and Olanzapine on Cognition (SEROLA) (clinicaltrials.gov) - Nov 5, 2012
P=N/A, N=11, Terminated, Sponsor: University of Aarhus
Recruiting --> Terminated; Due to recruitment problems N=100 --> 11
- galantamine hydrobromide / Generic mfg., citicoline / Generic mfg.
Trial completion: STAR-1: Use of Galantamine and CDP-choline (Citicoline) to Treat Adults With Schizophrenia (clinicaltrials.gov) - Nov 5, 2012
P2, N=43, Completed, Sponsor: Georgetown University
N=100 --> 11 Recruiting --> Completed
- Trial termination: Risks for Insulin Resistance and Metabolic Syndrome Between Major Depressive Disorder (MDD) or MDD With Psychotic Features (clinicaltrials.gov) - Nov 1, 2012
P=N/A, N=14, Terminated, Sponsor: Massachusetts General Hospital
Recruiting --> Completed Recruiting --> Terminated; PI left Massachusetts General Hospital Inpatient service
- Enrollment change: Risks for Insulin Resistance and Metabolic Syndrome Between Major Depressive Disorder (MDD) or MDD With Psychotic Features (clinicaltrials.gov) - Nov 1, 2012
P=N/A, N=14, Terminated, Sponsor: Massachusetts General Hospital
Recruiting --> Terminated; PI left Massachusetts General Hospital Inpatient service N=60 --> 14
- | Trial completion, Enrollment change: Genetic Research in Schizophrenia Using DNA Markers and Clinical Phenotypes (clinicaltrials.gov) - Oct 31, 2012
P=N/A, N=538, Completed, Sponsor: Department of Veterans Affairs
N=60 --> 14 N=3000 --> 538 | Recruiting --> Completed
- Clinical: Neurobiology of a Mutation in Glycine Metabolism in Psychotic Disorders (clinicaltrials.gov) - Oct 31, 2012
P0, N=2, Enrolling by invitation, Sponsor: Mclean Hospital
- niacin extended-release formulation / Generic mfg.
New P3 trial: Niapsan as Add -on Therapy to Antipsychotic Treatment in First Episode Psychosis (clinicaltrials.gov) - Oct 31, 2012
P3, N=45, Recruiting, Sponsor: Capital District Health Authority, Canada
- isradipine / Generic mfg.
Enrollment open: Evaluating Isradipine for Cognitive Enhancement in Schizophrenia and Schizoaffective Disorder (clinicaltrials.gov) - Oct 31, 2012
P=N/A, N=15, Recruiting, Sponsor: Katherine Burdick
N=3000 --> 538 | Recruiting --> Completed Not yet recruiting --> Recruiting
- Trial completion: Genetic Research in Schizophrenia Using DNA Markers and Clinical Phenotypes (clinicaltrials.gov) - Oct 31, 2012
P=N/A, N=538, Completed, Sponsor: Department of Veterans Affairs
Not yet recruiting --> Recruiting Recruiting --> Completed
- ||||||| aripiprazole / Generic mfg.
Trial completion: Oral Aripiprazole Open-Label Rollover Study (clinicaltrials.gov) - Oct 30, 2012
P3, N=85, Completed, Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
Recruiting --> Completed Active, not recruiting --> Completed
- ||||||| zicronapine (Lu31-130) / Lundbeck
Trial completion: Safety and Efficacy of Zicronapine in Patients With Schizophrenia (clinicaltrials.gov) - Oct 29, 2012
P3, N=160, Completed, Sponsor: H. Lundbeck A/S
Active, not recruiting --> Completed Active, not recruiting --> Completed
- || encenicline (EVP-6124) / Forum Pharmaceuticals, Mitsubishi Tanabe
New P3 trial: Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy (clinicaltrials.gov) - Oct 28, 2012
P3, N=700, Recruiting, Sponsor: FORUM Pharmaceuticals Inc
- New P2 trial: An Open Study of Sulforaphane-rich Broccoli Sprout Extract in Patients With Schizophrenia (clinicaltrials.gov) - Oct 28, 2012
P2, N=10, Recruiting, Sponsor: Chiba University
- Enrollment open: An Open Study of Sulforaphane-rich Broccoli Sprout Extract in Patients With Schizophrenia (clinicaltrials.gov) - Oct 28, 2012
P2, N=10, Recruiting, Sponsor: Chiba University
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- |||||||||| encenicline (EVP-6124) / Forum Pharmaceuticals, Mitsubishi Tanabe
New P3 trial: Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy (clinicaltrials.gov) - Oct 24, 2012
P3, N=700, Recruiting, Sponsor: EnVivo Pharmaceuticals, Inc.
- || encenicline (EVP-6124) / Forum Pharmaceuticals, Mitsubishi Tanabe
New P3 trial: A 26-Week Extension Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy (clinicaltrials.gov) - Oct 24, 2012
P3, N=1050, Recruiting, Sponsor: FORUM Pharmaceuticals Inc
- | aripiprazole / Generic mfg., ziprasidone / Generic mfg.
New P4 trial: Safety and Efficacy of Aripiprazole and Ziprasidone Among Schizophrenic Patients With Metabolic Syndrome (clinicaltrials.gov) - Oct 23, 2012
P4, N=175, Completed, Sponsor: University of Malaya